The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes

Yuichi Murakami, Yoshizo Kimura, Akihiko Kawahara, Shohei Mitsuyasu, Hidetoshi Miyake, Kaoru Tohyama, Yoshio Endo, Nao Yoshida, Yutaka Imamura, Kosuke Watari, Mayumi Ono, Takashi Okamura, Michihiko Kuwano

Research output: Contribution to journalArticle

Abstract

5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-derived cell lines, MDS-L, an MDS-derived cell line with a relatively low CDA expression level, was found to be the most sensitive to 5AC. Combination with tetrahydrouridine, an inhibitor of CDA, synergistically potentiated the cytotoxic effect of 5AC. Treatment with 5AC markedly enhanced the expression level of CDA mRNA and showed demethylation at CpG sites in the 5'-flanking region of the CDA gene. We further compared the protein expression levels of CDA in matched clinical samples before and after treatment with 5AC in bone marrow cells from 8 MDS patients by an immunohistochemical analysis. The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. In contrast, the 5 remaining patients, whose CDA expression showed no augmentation, observed no clinical benefit. Taken together, the optimized determination of the CDA expression levels before and after 5AC treatment, and the methylation status at CpG sites of 5'-flanking region of the CDA gene, may contribute to the development of precise 5AC therapy for MDS.

Original languageEnglish
Pages (from-to)2270-2281
Number of pages12
JournalOncotarget
Volume10
Issue number23
DOIs
Publication statusPublished - Mar 19 2019

Fingerprint

Cytidine Deaminase
Azacitidine
Myelodysplastic Syndromes
Genes
Therapeutics
5' Flanking Region
Tetrahydrouridine
Cell Line
Bone Marrow Cells
Methylation

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Murakami, Y., Kimura, Y., Kawahara, A., Mitsuyasu, S., Miyake, H., Tohyama, K., ... Kuwano, M. (2019). The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. Oncotarget, 10(23), 2270-2281. https://doi.org/10.18632/oncotarget.26784

The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. / Murakami, Yuichi; Kimura, Yoshizo; Kawahara, Akihiko; Mitsuyasu, Shohei; Miyake, Hidetoshi; Tohyama, Kaoru; Endo, Yoshio; Yoshida, Nao; Imamura, Yutaka; Watari, Kosuke; Ono, Mayumi; Okamura, Takashi; Kuwano, Michihiko.

In: Oncotarget, Vol. 10, No. 23, 19.03.2019, p. 2270-2281.

Research output: Contribution to journalArticle

Murakami, Y, Kimura, Y, Kawahara, A, Mitsuyasu, S, Miyake, H, Tohyama, K, Endo, Y, Yoshida, N, Imamura, Y, Watari, K, Ono, M, Okamura, T & Kuwano, M 2019, 'The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes' Oncotarget, vol. 10, no. 23, pp. 2270-2281. https://doi.org/10.18632/oncotarget.26784
Murakami, Yuichi ; Kimura, Yoshizo ; Kawahara, Akihiko ; Mitsuyasu, Shohei ; Miyake, Hidetoshi ; Tohyama, Kaoru ; Endo, Yoshio ; Yoshida, Nao ; Imamura, Yutaka ; Watari, Kosuke ; Ono, Mayumi ; Okamura, Takashi ; Kuwano, Michihiko. / The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. In: Oncotarget. 2019 ; Vol. 10, No. 23. pp. 2270-2281.
@article{55a92f92a38e4e7b97272e9df1a3baba,
title = "The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes",
abstract = "5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-derived cell lines, MDS-L, an MDS-derived cell line with a relatively low CDA expression level, was found to be the most sensitive to 5AC. Combination with tetrahydrouridine, an inhibitor of CDA, synergistically potentiated the cytotoxic effect of 5AC. Treatment with 5AC markedly enhanced the expression level of CDA mRNA and showed demethylation at CpG sites in the 5'-flanking region of the CDA gene. We further compared the protein expression levels of CDA in matched clinical samples before and after treatment with 5AC in bone marrow cells from 8 MDS patients by an immunohistochemical analysis. The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. In contrast, the 5 remaining patients, whose CDA expression showed no augmentation, observed no clinical benefit. Taken together, the optimized determination of the CDA expression levels before and after 5AC treatment, and the methylation status at CpG sites of 5'-flanking region of the CDA gene, may contribute to the development of precise 5AC therapy for MDS.",
author = "Yuichi Murakami and Yoshizo Kimura and Akihiko Kawahara and Shohei Mitsuyasu and Hidetoshi Miyake and Kaoru Tohyama and Yoshio Endo and Nao Yoshida and Yutaka Imamura and Kosuke Watari and Mayumi Ono and Takashi Okamura and Michihiko Kuwano",
year = "2019",
month = "3",
day = "19",
doi = "10.18632/oncotarget.26784",
language = "English",
volume = "10",
pages = "2270--2281",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes

AU - Murakami, Yuichi

AU - Kimura, Yoshizo

AU - Kawahara, Akihiko

AU - Mitsuyasu, Shohei

AU - Miyake, Hidetoshi

AU - Tohyama, Kaoru

AU - Endo, Yoshio

AU - Yoshida, Nao

AU - Imamura, Yutaka

AU - Watari, Kosuke

AU - Ono, Mayumi

AU - Okamura, Takashi

AU - Kuwano, Michihiko

PY - 2019/3/19

Y1 - 2019/3/19

N2 - 5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-derived cell lines, MDS-L, an MDS-derived cell line with a relatively low CDA expression level, was found to be the most sensitive to 5AC. Combination with tetrahydrouridine, an inhibitor of CDA, synergistically potentiated the cytotoxic effect of 5AC. Treatment with 5AC markedly enhanced the expression level of CDA mRNA and showed demethylation at CpG sites in the 5'-flanking region of the CDA gene. We further compared the protein expression levels of CDA in matched clinical samples before and after treatment with 5AC in bone marrow cells from 8 MDS patients by an immunohistochemical analysis. The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. In contrast, the 5 remaining patients, whose CDA expression showed no augmentation, observed no clinical benefit. Taken together, the optimized determination of the CDA expression levels before and after 5AC treatment, and the methylation status at CpG sites of 5'-flanking region of the CDA gene, may contribute to the development of precise 5AC therapy for MDS.

AB - 5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-derived cell lines, MDS-L, an MDS-derived cell line with a relatively low CDA expression level, was found to be the most sensitive to 5AC. Combination with tetrahydrouridine, an inhibitor of CDA, synergistically potentiated the cytotoxic effect of 5AC. Treatment with 5AC markedly enhanced the expression level of CDA mRNA and showed demethylation at CpG sites in the 5'-flanking region of the CDA gene. We further compared the protein expression levels of CDA in matched clinical samples before and after treatment with 5AC in bone marrow cells from 8 MDS patients by an immunohistochemical analysis. The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. In contrast, the 5 remaining patients, whose CDA expression showed no augmentation, observed no clinical benefit. Taken together, the optimized determination of the CDA expression levels before and after 5AC treatment, and the methylation status at CpG sites of 5'-flanking region of the CDA gene, may contribute to the development of precise 5AC therapy for MDS.

UR - http://www.scopus.com/inward/record.url?scp=85064878902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064878902&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26784

DO - 10.18632/oncotarget.26784

M3 - Article

VL - 10

SP - 2270

EP - 2281

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -